MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Alirocumab (Praluent®)

Selected References:

  • Anderson PO. 2021. Monoclonal antibodies during breastfeeding. Breastfeeding Medicine. 16(8): 591-93.
  • Noseda R, et al. 2024. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. Clinical pharmacology and therapeutics, 10.1002/cpt.3269. Advance online publication.
  • Praluent® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbledt.pdf, Accessed May 28, 2024
  • Vuignier Y, et al. 2021. Exposure to alirocumab during the first trimester of pregnancy: A case report. Birth Defects Research. 113(15): 1156–60.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.